A practical reference on DAC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-04 and is reviewed periodically as new material appears.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
=== Aldosterone feedback === Feedback by aldosterone concentration itself is of a nonmorphological character (that is, other than changes in the cells' number or structure) and is poor, so the electrolyte feedbacks predominate, short term.
A thermal shift assay (TSA) measures the stability of a protein by the change in its thermal denaturation temperature. This is done under varying conditions, such as variations in drug concentration, buffer formulation (pH or ionic strength), redox potential, or sequence mutation. The most common method for measuring protein thermal shifts is differential scanning fluorimetry (DSF). DSF methodology includes techniques such as nanoDSF, which relies on the intrinsic fluorescence from native tryptophan or tyrosine residues, and Thermofluor, which utilizes extrinsic fluorogenic dyes. The binding of low molecular weight ligands can increase the thermal stability of a protein, as described by Daniel Koshland (1958) and Kaj Ulrik Linderstrøm-Lang and Schellman (1959). Almost half of enzymes require a metal ion co-factor. Thermostable proteins are often more useful than their non-thermostable counterparts, e.g., DNA polymerase in the polymerase chain reaction, so protein engineering often includes adding mutations to increase thermal stability. Protein crystallization is more successful for proteins with a higher melting point and adding buffer components that stabilize proteins improve the likelihood of protein crystals forming. If examining pH then the possible effects of the buffer molecule on thermal stability should be taken into account along with the fact that pKa of each buffer molecule changes uniquely with temperature. Additionally, any time a charged species is examined the effects of the counterion should be accounted for.
== Ecology == Like most Bacilli, the most common ecosystem of Bacillus cereus is the soil. In concert with arbuscular mycorrhiza (and Rhizobium leguminosarum in clover), they can up-regulate plant growth in heavy metal soils by decreasing heavy metal concentrations via bioaccumulation and biotransformation in addition to increasing phosphorus, nitrogen, and potassium uptake in certain plants. B. cereus was also shown to aid in survival of earthworms in heavy metal soils resulting from the use of metal-based fungicides, showing increases in biomass, reproduction and reproductive viability, and a decrease in metal content of tissues in those inoculated with the bacterium. These results suggest strong possibilities for its application in ecological bioremediation. Evidence of bioremediation potential by Bacillus cereus was also found in the aquatic ecosystem, where organic nitrogen and phosphorus wastes polluting a eutrophic lake were broken down in the presence of B. cereus. In a study measuring the ability of B. cereus to degrade keratin in chicken feathers, bacteria were found to sufficiently biodegrade keratin via hydrolytic mechanisms. These results indicate its potential to degrade keratinous waste from the poultry industry for potential recycling of the byproducts. B. cereus competes with Gram-negative bacteria species such as Salmonella and Campylobacter in the gut; its presence reduces the number of Gram-negative bacteria, specifically via antibiotic activity via enzymes such as cereins that impede their quorum sensing ability and exhibit bactericidal activity.
In December 2018, Collins took part in a one-off celebrity special of All Together Now. Collins first performed "Big Spender" by Shirley Bassey where she received a score of 88 after impressing the judges with her vocal ability, which secured her a place in the top 3. She then sang "This Is Me" by Keala Settle and The Greatest Showman ensemble and subsequently finished in third place with a score of 39. Between January and February 2019, Collins took part in the eleventh series of the ITV skating competition Dancing on Ice, alongside professional partner Matt Evers. Her debut performance saw her skate to "Crazy in Love" by Beyoncé, in which she performed the splits on ice and attempted to lift her partner Evers at the end of the routine. She scored 16.0 out of 40.0 points, ultimately receiving the most votes from the public and got through to the next week, with 28.23% of the vote. Following her performance to "Diamonds Are a Girl's Best Friend" in Musicals Week, in which Collins was dressed as Marilyn Monroe and concluded with her being suspended in the air on a giant diamond ring, saw the couple receive 13.0 out of 40.0, the lowest marks of that year's series. Collins subsequently had an on-screen argument with judge Jason Gardiner, who made comments about her weight and lack of commitment to the series, and accused him of selling stories about her to the press.
== Risks and side effects == Several studies have found fat grafting of the lip to be one of the best methods of maintaining a semi-permanent fuller and softer lip. When the lips are overfilled, the results can be comic, often supplying fodder to tabloid newspapers and offbeat websites. This look is sometimes mockingly called a 'trout pout.' Overaggressive injections can lead to lumpiness while too little can result in ridges. Common reactions can range from redness, swelling or itching at the injection site(s). Other possible complications include bleeding, uneven lips, movement of the implants, or extrusion, when an implant breaks through the outermost surface of the skin. Swelling and bruising can last from several days to a week. Some patients are allergic to the common local anesthetics like lidocaine and probably should not consider lip injections. Some react badly to the skin test that patients must take before receiving collagen. Other patients who should forego procedures to the lip include those who have active skin conditions like cold sores, blood clotting problems, infections, scarring of the lips or certain diseases like diabetes or lupus that cause slower healing. Patients with facial nerve disorders, severe hypertension or recurrent herpes simplex lesions should also eschew lip augmentation. As in all surgeries, smokers complicate completion of their procedure as well as the speed of healing. Fat transfer can last longer than other injected materials but can have lumping or scarring effects.
Sources: en.wikipedia.org
The cornea is the transparent front part of the eyeball which covers the iris, pupil, and anterior chamber. Along with the anterior chamber and lens, the cornea refracts light, accounting for approximately two-thirds of the eye's total optical power. In humans, the refractive power of the cornea is approximately 43 dioptres. The cornea can be reshaped by surgical procedures such as LASIK. While the cornea contributes most of the eye's focusing power, its focus is fixed. Accommodation (the refocusing of light to better view near objects) is accomplished by changing the geometry of the lens. Medical terms related to the cornea often start with the prefix "kerat-" from the Greek word κέρας, horn.
== Simulating wound healing from a growth perspective == Considerable effort has been devoted to understanding the physical relationships governing wound healing and subsequent scarring, with mathematical models and simulations developed to elucidate these relationships. The growth of tissue around the wound site is a result of the migration of cells and collagen deposition by these cells. The alignment of collagen describes the degree of scarring; basket-weave orientation of collagen is characteristic of normal skin, whereas aligned collagen fibers lead to significant scarring. It has been shown that the growth of tissue and extent of scar formation can be controlled by modulating the stress at a wound site. The growth of tissue can be simulated using the aforementioned relationships from a biochemical and biomechanical point of view. The biologically active chemicals that play an important role in wound healing are modeled with Fickian diffusion to generate concentration profiles. The balance equation for open systems when modeling wound healing incorporates mass growth due to cell migration and proliferation. Here the following equation is used: Dtρ0 = Div (R) + R0, where ρ represents mass density, R represents a mass flux (from cell migration), and R0 represents a mass source (from cell proliferation, division, or enlargement). Relationships like these can be incorporated into an agent-based models, where the sensitivity to single parameters such as initial collagen alignment, cytokine properties, and cell proliferation rates can be tested.
== Integrins == Integrins function as the major cell receptor for extracellular matrix protein. These receptors comprise an α and β transmembrane subunit, which are noncovalently bound. Collagen binding is primarily provided by integrins α1β1, α2β1, α10β1 and α11β1. Integrin α1β1 binds to collagen via the MIDAS motif in the α subunit I domain. It preferentially binds collagens IV, VI and type XIII collagen, but also fibril-forming collagens. Specific binding sites in collagen I and IV have been identified. This receptor is situated mainly on mesenchymal cells. Functions include: fibroblast proliferation; regulation of collagen synthesis and MMP expression; response to renal injury. Integrin α2β1 preferentially binds fibril-forming collagens. Specific binding sites in collagen I and III have been identified. Integrin α2β1 is expressed mainly on epithelial cells and platelets. Functions include: platelet adhesion - the most abundant receptor for collagen in platelets; branching morphogenesis; mast cell activation; keratinocyte adhesion and it is the main regulator of cell migration. Integrin α10β1 preferentially binds collagens IV and VI, but also collagen II. It is expressed on chondrocytes and cardiac muscle. Involved in growth plate morphogenesis and function. Integrin α11β1 is expressed by mesenchymal cells in some parts of embryo during its development and also in muscles in adults: it preferably binds fibrillar collagen. Integrin receptors capable of collagen binding could, according to results of (Garnotel R et al.
== Structure == The C4 Domain at the C-terminus is not removed in the post-translational process, and as a result, the structure of the fibers are linked in a "head-to-head" format instead of in a parallel fashion. It also lacks a glycine in every third amino acid residue that is responsible for the tight collagen helix, as a result it will be more flexible and kinked than other types of collagen.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.